Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “NURIX THERAPEUTICS, INC.”

14 pharma patents match "NURIX THERAPEUTICS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 14
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 14 pharmaceutical patents matching "NURIX THERAPEUTICS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

14 results for “NURIX THERAPEUTICS, INC.” · 30,257 patents in full index Clear search

  1. US 12377106

    Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK

    NURIX THERAPEUTICS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12234230

    Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

    NURIX THERAPEUTICS, INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  3. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    NURIX THERAPEUTICS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  4. US 12091426

    Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

    NURIX THERAPEUTICS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  5. US 12049471

    Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

    NURIX THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  6. US 12016860

    Combination therapies with Cbl-b inhibitor compounds

    NURIX THERAPEUTICS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  7. US 11951133

    3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

    NURIX THERAPEUTICS, INC. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  8. US 11866442

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    NURIX THERAPEUTICS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  9. US 11820781

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    NURIX THERAPEUTICS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  10. US 11739101

    Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

    NURIX THERAPEUTICS, INC. · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  11. US 11530229

    Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

    NURIX THERAPEUTICS, INC. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  12. US 11479556

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    NURIX THERAPEUTICS, INC. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  13. US 11464802

    3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

    NURIX THERAPEUTICS, INC. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  14. US 11401267

    Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

    NURIX THERAPEUTICS, INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted